报告显示，兆新股份依托"精细化工+新能源"双轮驱动战略，交出营收、净利双增长的答卷。在精细化 工领域，公司通过产品升级巩固优势，凭借工艺降本与订单结构优化，在原材料价格波动的环境下实 现"量增价稳"。同时，公司持续开拓高附加值领域，研发并推广新款环保气雾剂及萘系化工新材料产 品。在新能源领域，公司通过光伏电站或分布式发电系统形成电力销售，同时积极拓展光伏电站业务版 图，目前已在安徽、江西、浙江、宁夏及四川等地成功运营管理10座光伏电站。 展望下半年，兆新股份表示，将继续深化新能源产业链纵向布局，同时向精细化工与新能源产业新兴场 景延伸。公司将进一步打造多维度增长曲线，在行业周期中构筑独特竞争壁垒，以持续稳健的业绩回馈 投资者，为长期价值增长打下坚实基础。 中证报中证网讯（王珞）8月26日晚，兆新股份（002256）披露2025年半年度报告。公司上半年实现营 业收入2.08亿元，同比增长29.99%；净利润307.25万元，同比增长47.06%。剔除股份支付影响后，净利 润达1865.38万元，同比增长1120.2%。 兆新股份称，公司业绩增长的背后，离不开人才激励机制的深度赋能。上半年，公司实施限制性股票与 ...

上峰水泥 20250826 摘要 上峰水泥 2025 年上半年营收下降 5%，但净利润大幅增长 44%，扣非 净利润增长超 30%，得益于资产优化和费用控制，管理、财务及销售费 用占比均下降。 西部地区（新疆、宁夏）贡献显著，西北地区毛利率高达 43.6%，远超 华东和西南，新疆市场通过错峰生产和价格维护实现较高利润。 环保、骨料、新能源等衍生业务稳健增长，骨料和新能源增量超 30%， 体现公司向绿色、新兴产业转型趋势。骨料业务销量增长 30%，毛利率 提升 2 个百分点，主要受益于宁夏区域增长和产品结构调整。 公司推行双轮驱动战略，加大新经济投资，尤其在半导体材料领域，投 资多个项目，多家企业筹备上市，股权投资贡献财务收益。 上半年熟料成本同比下降 25 元/吨，水泥成本下降 10.67 元/吨，主要受 益于煤价下降和替代原料使用，综合成本下降约 13%。 水泥行业面临反内卷政策和治理超产准备，工信部将发布稳增长方案， 推动备案产能与实际产能统一，预计未来两年内淘汰约 25%产能。 公司资金储备充足，通过转移资金至其他流动和非流动资产，保障投资 项目资金来源，并积极进行降本增效，综合能耗降至 100 标煤以 ...

8月26日，香飘飘发布2025年半年报。当中披露，2025年上半年，公司实现营收10.35亿元，同比下降 12.21%，净亏损0.97亿元。其中，冲泡业务实现营收4.23亿元；即饮业务实现营收5.91亿元，同比增长 8.03%。 第三季度，将进入冲泡业务旺季启动阶段，公司将积极做好渠道备货与库存管理工作，为第四季度冲泡 产品销售旺季打下基础；与此同时，公司将继续加强礼品样板市场打造工作，总结积累成功经验，并计 划推出升级的礼品装产品，满足更多消费者需求，持续开拓礼品市场。 下半年，公司将加大新品推出的力度，为未来的市场开拓积蓄势能。在新产品与赛道探索上，公司会继 续围绕"健康化"的研发思路推进产品创新。其中，冲泡业务将推出新口味及"功能化"的健康新品并开展 试销探测；即饮业务计划持续推出更多杯装新品类产品，积极探索新的赛道，持续提升成长空间。 （企业公告） 公告指出，2025年上半年，面对外部消费环境变化，公司坚持"双轮驱动"战略，围绕"守正、稳进、创 变"的年度经营基调，积极落实"冲泡业务稳健修复"及"即饮业务加速拓展"的策略，落实各项经营举 措，逐步取得一定成效，第二季度营业收入实现同比略增，但受一季度影 ...

证券代码： 002531 证券简称：天顺风能 天顺风能(苏州)股份有限公司 投资者关系活动记录表 编号：2025-002 投资者关系活动 类别 ☑ 特定对象调研 □ 分析师会议 □ 媒体采访 □ 业绩说明会 □ 新闻发布会 □ 路演活动 □ 现场参观 ☑ 其他：电话会议 参与单位名称及 人员姓名 参会人员名单见后续附表 时间 2025 年 08 月 22 日(周五) 上午 9:00-10:00 地点 电话会议 上市公司接待人 员姓名 1、董事会秘书 朱彬； 2、投资者关系总监 邓子龙； 交流内容及具体 问答记录 一、公司经营情况介绍 2025 年上半年，天顺风能坚定推进"新能源装备制造+零碳 实业发展"双轮驱动战略，持续深化战略转型与全球化布局。 海工装备制造板块优化全球产能布局，广东阳江基地进入投 产冲刺阶段，射阳二期扩建启动，德国基地建设稳步推进，面向 "国内 + 海外"多元市场形成协同业务体系，依托通州湾基地 拓展高附加值海工业务；零碳实业板块在风电资源开发等方面取 得阶段性进展，在建项目按计划推进，绿电交易探索取得进展， 自营电站并网容量的增长也提升了财务韧性。展望下半年，公司 将坚持"制造 + 服务 ...

Investment Rating - The report maintains an "Accumulate" rating for the company [2][4]. Core Views - The company achieved a total revenue of 888 million yuan in the first half of 2025, representing a year-on-year growth of 9.34%, and a net profit attributable to shareholders of 102 million yuan, up 7.37% year-on-year, which aligns with expectations [3]. - The company's disposable hygiene products for pets continue to grow rapidly, with revenue from these products reaching 834 million yuan, a year-on-year increase of 9.31%. Specifically, pet pads generated 764 million yuan (up 7.28%), while pet diapers saw a significant increase of 40.58% to 66 million yuan [4]. - The company is increasing its investment in domestic self-owned brands, utilizing a multi-channel approach to expand market share in the domestic pet industry [4]. - The gross margin slightly improved to 18.97%, while the net margin experienced a slight decline to 11.5% due to increased asset impairment losses [4]. - The company is expected to continue its "overseas + domestic" dual circulation and "ODM/OEM + self-owned brand" dual-drive strategy, focusing on enhancing competitiveness [4]. Financial Summary - The company forecasts total revenues of 2,073 million yuan for 2025, 2,435 million yuan for 2026, and 2,836 million yuan for 2027, with corresponding net profits of 248 million yuan, 295 million yuan, and 349 million yuan respectively [5]. - The diluted earnings per share (EPS) are projected to be 1.34 yuan for 2025 and 1.60 yuan for 2026, with price-to-earnings (PE) ratios of 20.1 and 16.9 respectively [6].

6月27日，华润啤酒发布公告称，侯孝海因有意投入更多时间于个人安排，决定辞任执行董事、董事会主席，且不再担任董事会辖下财务委员会主席，执 行委员会、购股权总务委员会成员。华润啤酒表示，侯孝海辞任后，董事会主席职位将暂时悬空，直至公司委任合适继任人。公司执行董事及总裁赵春武 暂时承担过渡期间董事会主席的工作及责任。截至今日，华润啤酒尚未正式公布新的"掌门人"。 赵春武出席了此次财报后举办的业绩发布会，他称，现任管理层对于下一步发展有着高度共识，对于此前侯孝海带领下的华润啤酒战略，以延续和发扬为 主，不会有太大改动。 新京报 记者 王子扬 中国基金报 记者 夏天 8月19日，华润啤酒发布2025年中期业绩：上半年营收239.42亿元，同比增长0.8%；股东应占溢利57.89亿元，同比增长23%。 侯孝海离职后，暂时承担董事会主席工作及责任的华润啤酒执行董事及总裁赵春武出席业绩说明会，提到侯孝海离职一事，他表示"舍不得"。 啤酒业务方面，华润啤酒上半年未经审计营业额为231.61亿元，同比增长2.6%；实现啤酒销量约648.7万千升，同比上升2.2%。高端啤酒产品持续发力， 上半年普高档及以上啤酒销量同比增长超过1 ...

安旭生物8月20日股价报42.05元，较前一交易日下跌1.20%。公司最新发布的2025年半年报显示，上半 年实现营收2.30亿元，扣非净利润2358.62万元，同比增长24.89%。 公司主营业务为POCT试剂及仪器的研发、生产与销售。报告期内，公司通过国际国内"双轮驱动"战 略，在海外市场不确定性增加的背景下，保持了经营韧性。国内市场方面，公司新获多项医疗器械注册 证，包括呼吸道病毒抗原检测笔、胸痛三联笔等产品。同时通过"安旭科"品牌开拓电商平台C端市场， 形成B端与C端双轨发展模式。 风险提示：投资有风险，入市需谨慎。公司面临海外市场政策变化、汇率波动等风险因素。 来源：金融界 ...

Core Viewpoint - Hangzhou Anxu Biotechnology Co., Ltd. has demonstrated operational resilience amid challenges in the in vitro diagnostics (IVD) industry, including intensified centralized procurement and changes in the international trade environment, by actively adjusting its market strategies [1][3]. Financial Performance - In the first half of 2025, the company reported revenue of 230 million yuan and a net profit of 23.5862 million yuan after deducting non-recurring items [1]. Market Strategy - The company has adopted a "dual-wheel drive" strategy focusing on both international and domestic markets to address uncertainties in overseas markets, leading to a strong adaptability in overall operations despite performance fluctuations [1][3]. - In the domestic market, Anxu Biotechnology successfully obtained multiple medical device registration certificates, including for respiratory virus antigen detection and influenza virus antigen testing kits, targeting essential healthcare needs [1][2]. Business Expansion - The company has developed a dual-track model of "deepening B-end and breaking into C-end" by leveraging the "Anxu Ke" brand to expand into e-commerce, resulting in steady sales growth in home health management products [2]. - Anxu Biotechnology has established a "global network + localized service" system to strengthen its presence in traditional markets such as Europe, Oceania, Asia, and Africa, while also extending into emerging markets to mitigate single-market risks [2]. Diversification - The company is actively expanding into new fields while consolidating its traditional advantages in point-of-care testing (POCT). Its subsidiary, Taimengle, focuses on pet medical testing, developing over a hundred testing solutions for various infectious diseases and health monitoring [2]. - The company has launched the GluMate chronic disease management app, integrating existing POCT products into a comprehensive solution that includes hardware, software, and data services [2]. Industry Outlook - The global IVD market is projected to grow from $109.2 billion in 2024 to $135.1 billion by 2029, with strong growth expected in microfluidic technology and pet medical testing segments [3]. - Despite the overall pressure on the industry in the first half of 2025, the company has shown innovative vitality and resilience through its integrated supply chain, global layout, and diversified business strategies, laying a solid foundation for long-term healthy development [3].

Core Viewpoint - Anxu Bio maintains operational resilience amid challenges in the in vitro diagnostic (IVD) industry, reporting a slight revenue decline but significant profit growth in the first half of 2025 [1][2][3] Group 1: Financial Performance - The company's revenue for the first half of 2025 was 230 million yuan, a year-on-year decrease of 7.42% [1] - The net profit excluding non-recurring items reached 24 million yuan, reflecting a year-on-year increase of 24.89% [1] Group 2: Market Strategy - Anxu Bio has adopted a "dual-wheel drive" strategy focusing on both domestic and international markets to counteract external uncertainties, such as delayed customer orders due to tariffs [1][2] - The company has successfully registered multiple medical device certifications, enhancing its product offerings in critical areas like infectious disease prevention and cardiovascular emergencies [1] Group 3: Business Expansion - The launch of the "Anxu Ke" brand has allowed the company to penetrate the C-end market through e-commerce, establishing a dual-track model of deepening B-end and breaking into C-end markets [2] - Anxu Bio is expanding its presence in the pet medical testing sector through its subsidiary, targeting a market projected to reach 84.1 billion yuan in 2024, growing at 5.6% [2] Group 4: Future Outlook - The global IVD market is expected to grow from 109.2 billion USD in 2024 to 135.1 billion USD by 2029, with strong growth in microfluidic technology and pet medical testing [3] - Anxu Bio's strategy aligns with industry trends by focusing on a diversified product matrix and expanding both domestic and international markets, positioning itself for long-term growth [3]

Core Insights - Zhejiang Yonghe Refrigeration Co., Ltd. reported a revenue of 2.445 billion yuan for the first half of 2025, representing a year-on-year growth of 12.39%, and a net profit attributable to shareholders of 271 million yuan, up 140.82% [1] Group 1: Business Performance - The growth in Yonghe's performance is driven by two main factors: the refrigerant segment benefiting from quota policy adjustments leading to improved supply-demand structure and rising product prices, and the optimization of product structure with enhanced production efficiency and quality in fluoropolymer materials [1][2] - The fluorocarbon chemical business generated 1.31 billion yuan in revenue, a year-on-year increase of 26.02%, with an average gross margin of 32.43%, up 12.15 percentage points from the previous year [2] - The fluoropolymer materials segment produced 27,300 tons, a 3.72% increase year-on-year, with gross profit rising 11.29% to 158 million yuan, and an average gross margin of 19.75%, up 2.73 percentage points [3] Group 2: Industry Context - Since 2024, China has implemented quota management for third-generation refrigerants, marking a new phase in supply-side management for the refrigerant industry [2] - The quota management is expected to drive mainstream product prices upward and optimize industry capacity structure, providing opportunities for major companies like Yonghe to expand market share and enhance profits [2] - The company is facing challenges in the fluoropolymer materials market due to supply-demand imbalances and intense price competition, prompting it to adopt strategies such as scaling up production capacity and refining cost control [2][3] Group 3: Strategic Insights - Yonghe's dual-driven strategy is expected to strengthen its complete industry chain, allowing for flexibility in switching between refrigerant upgrades and the development of domestic substitute products [3] - The company's ability to implement differentiated strategies for its various business segments demonstrates its keen market analysis capabilities and effective strategic execution [3]